Navigation Links
Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
Date:9/19/2013

David SchullExecutive Director, Investor Relations & Corp Comm

Media ContactsAmbit Biosciences, Inc.

Russo Partners858-334-2125

619-308-6541/212-845-4271mgraham@ambitbio.com

ian.stone@russopartnersllc.com / david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
2. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
3. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
4. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. Natural Skin Care Solution, Probiotic Action Announces the Use of Their Probiotic Cleanser As a Anti-Acne Body Wash
9. Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
10. Neogen announces 1st quarter results conference call
11. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed ... Technologies Summit in San Francisco to take first place ... Silicon Valley investors and technology elites as the premier ... positions Briteseed to move on to the final ... compete with other elite innovation finalists for a $125,000 ...
(Date:11/22/2014)... November 22, 2014 Respiratory therapy ... the proper management of life-like respiratory ailments using ... devices . Grand Rapids-based, Michigan Instruments Inc. developers ... two of the respiratory simulation units to the ... Grand Valley and Muskegon Community College are collaborating ...
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... , Nov. 21, 2014   TRU-D SmartUVC LLC ... feature their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, at ... week from Nov. 23 to 26 at Stand 23. ... the United Kingdom,s largest infection-related event ... prevention societies to one of the leading events of its ...
Breaking Biology Technology:Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3
... in product ... identification, INDIANAPOLIS, ... announced the introduction of a color differentiation,system for U-100 insulin products ... Humalog(R) (insulin lispro,injection [rDNA origin]) and Humulin(R) (regular insulin human injection,USP ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... 1/2a study,demonstrating that repeat administration with TRU-015 ... in rheumatoid arthritis,(RA) signs and symptoms based ... also announced positive results following preliminary,analyses from ...
... Call at 8:30 a.m. Eastern Time Today to ... ... Inc. (Nasdaq: BCRX ) today announced results of an,exploratory Phase ... for acute serious or potentially,life-threatening influenza. The Phase 2 trial compared ...
Cached Biology Technology:Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 2Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 3Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 4Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States 5Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 2BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 3BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 4BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 5BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza 6
(Date:11/6/2014)... for a predator. Except when that predator runs so fast ... to its size, is the fastest creature on Earth. Some ... second (at about five miles per hour). The fastest human ... gold from the tiger beetle, a person would have to ... has a problem. At peak speeds, everything becomes a blur. ...
(Date:11/5/2014)... in their ability to identify scents and odors. ... perceptual evaluation of odors, with women outperforming men on ... differences in olfactory detection may play a role in ... perception of smell, which is naturally linked to associated ... suggested to be cognitive or emotional, rather than perceptual. ...
(Date:11/4/2014)... — Think about the way our bodies are assembled ... know that they are supposed to become a nerve ... find the correct place and alignment? Researchers at the ... , In a new study, UM researchers describe the ... surrounding neighbors, at the head-trunk region. Their discovery may ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2The female nose always knows: Do women have more olfactory neurons? 2The inside story: How the brain and skull stay together 2
... be used to study COX deficiencies in humans, ... view the,earliest stages of mitochondrial impairments that lead ... the University of,Oregon., COX deficiencies refer to a ... mitochondrion of every cell. Mitochondria are crucial,cellular workhorses ...
... is being employed to develop revolutionary drug delivery methods ... could benefit millions of patients. Chemists at The ... drugs in plastics, using methods that do not damage ... at the cutting edge of modern medical treatment. ...
... whether the Neanderthals died out because of competition ... conditions. Although scientists have gained increased knowledge of ... the climatic character at the time of the ... team of researchers, published this week in the ...
Cached Biology News:Zebrafish to shed light on human mitochondrial diseases 2Using green chemistry to deliver cutting-edge drugs 2Using green chemistry to deliver cutting-edge drugs 3Using green chemistry to deliver cutting-edge drugs 4Climate -- no smoking gun for Neanderthals 2
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
...
Biology Products: